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ABSTRACT Immunoneutralization studies with a mono-
clonal antibody to somatomedin C (Sm-C) were undertaken to
further determine the role of this peptide in cellular prolifera-
tion. For our model we used density-arrested cultures of
BALB/c 3T3 cells. Transient exposure of these cells to platelet-
derived growth factor enables them to respond to platelet-poor
plasma by progressing through the G, stage and undergoing
renewed DNA synthesis. In this system, the combination of
nanogram concentrations of Sm-C and epidermal growth fac-
tor can fully substitute for plasma, and microgram concentra-
tions of insulin can substitute for Sm-C by crossreacting with
the Sm-C receptor. We now show that a monoclonal antibody
to Sm-C, which in defined medium blocks the mitogenic effect
of Sm-C but not insulin, also blocks the stimulation of DNA
synthesis by human plasma or calf serum. Furthermore, by
adding the antibody at progressively later times during G1, we
show that these cells escape from their dependence on Sm-C
for DNA synthesis after traversing GI to a point at or near the
G1/S boundary.
The somatomedins are a family of polypeptide hormones
that mediate many of the growth promoting actions of
growth hormone (1-3). Somatomedin C (Sm-C) and insulin-
like growth factor I (IGF-I) are synonyms for a single-chain
70-amino acid basic somatomedin that is more growth-hor-
mone dependent and more mitogenic than the other human
somatomedin, insulin-like growth factor II. The latter is a
neutral molecule that is more insulin-like in its actions and is
present at levels 3 times greater than those of Sm-C/IGF-I.
Sm-C will restore linear growth in either hypophysectomized
rats or in mice with a hereditary form of hypopituitarism
(Snell dwarf strain) (4, 5). Although nanogram concentra-
tions of Sm-C have been reported to promote DNA synthesis
and/or cell replication in many different cell types, the most
detailed studies have been made in mouse mesenchyme-de-
rived BALB/c 3T3 cells (6). These cells, which become qui-
escent after having been grown to confluency in 10% serum,
will respond to fresh serum-containing medium by progress-
ing through the G1 stage and undergoing renewed DNA syn-
thesis. Platelet-poor plasma (PPP), which is prepared by re-
moving formed blood elements before clotting takes place,
will not stimulate these quiescent cells to traverse G1 unless
they are first exposed to platelet-derived growth factor
(PDGF) (7). Stiles et al. (8) showed that PPP from hypophy-
sectomized rats was ineffectual in stimulating DNA synthe-
sis unless supplemented with added Sm-C. More recently,
Leof et al. (9, 10) have shown that a combination of Sm-C
and epidermal growth factor (EGF) can completely replace
plasma in permitting PDGF-treated cells to progress to DNA
synthesis. At high doses (1 AsM), insulin can serve as a soma-
tomedin surrogate by binding to the Sm-C receptor (11). The
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development of a specific monoclonal antibody to Sm-C0 has
now made it possible to determine the consequences of se-
lectively neutralizing this peptide in defined medium, in hu-
man plasma, and in calf serum.
MATERIALS AND METHODS
Cell Culture. BALB/c 3T3 cells (clone A-31) were cul-
tured in a 1:1 mixture of Dulbecco's modified Eagle medium
and Ham's F-12 (DME medium/F-12), supplemented with
10% calf serum. Cells were grown to confluence in 96-well
microtiter plates (Nunc, Roskilde, Denmark) in 0.2 ml of se-
rum-containing culture medium. Within 48 hr of reaching
confluence, the medium was replaced for 5 hr with serum-
free DME medium/F-12 containing PDGF at 20 ng/well.
The PDGF-containing medium was replaced with culture
medium containing [3H]methyl thymidine (6 Ci/mmol; 1 Ci
= 37 GBq; Schwarz/Mann) at 1 ,uCi per well, and either
plasma or growth factors with or without antibody. After 28
hr, the cells were fixed by the addition of 1 M ascorbic acid
(0.06 ml per well), and the plates were processed for autora-
diography or thymidine incorporation.
Thymidine incorporation was determined after the mono-
layers were rinsed in serum-free DME medium/F-12, fixed
and washed twice in 5% trichloroacetic acid at 4°C and then
solubilized in 0.1 M NaOH with 1% sodium dodecyl sulfate
for counting. All results are expressed as the mean of tnrpli-
cate wells ± SEM. In some experiments, autoradiography
was performed according to the method of Antoniades et al.
(12).
Growth Factors and Sera. Sm-C was purified from human
plasma by the method of Svoboda et al. (13). The prepara-
tion used in this study was a pool of side fractions from the
terminal HPLC purification step. PDGF was prepared from
heated extracts of clinically outdated human platelets chro-
matographed on CM Sephadex, followed by further purifica-
tion on Blue Sepharose and Bio-Gel 150 as described (14,
15). EGF was prepared by the method of Savage and Cohen
(16), and was the gift of E. O'Keefe. Human PPP (inactivat-
ed at 56°C for 30 min) was prepared as described by Pledger
et al. (7) and calf serum was purchased from Hyclone (Lo-
gan, UT).
Monoclonal Antibody to Sm-C (sm-1.2). The monoclonal
antibody to Sm-C was produced in a mouse hyperimmunized
over 6 weeks with highly purified Sm-C conjugated to mouse
albumin. Prior to fusion with P3X63Ag8.653 myeloma cells,
the splenocytes were boosted in vitro by a 5-day reexposure
to pure Sm-C in thymocyte-conditioned medium. Anti-soma-
Abbreviations: Sm-C, somatomedin C; PDGF, platelet-derived
growth factor; PPP, platelet-poor plasma; EGF, epidermal growth
factor; IGF-I and -II, insulin-like growth factors I and II.
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tomedin-producing hybrids were cloned and amplified by in-
traperitoneal injection into pristane-primed BALB/c mice.
The immunoglobulin fraction from the clone designated sm-
1.2 was further purified from ascites fluid by sequential pre-
cipitation in 18% and 15% sodium sulfate (17).
The antibody was a K IgG1 and bound Sm-C with an affini-
ty constant of L.Q9 x 1010 liters/mol. IGF-II (gift of R. Hum-
bel, Zurich) and multiplication-stimulating activity (Collabo-
rative Research, Lexington, MA) were, respectively, 5%
and 1% as potent as Sm-C. The affinity of the antibody was
negligible for chymotryptic fragments of Sm-C, various insu-
lins, bovine proinsulin, human growth hormone, and EGF.
RESULTS AND DISCUSSION
Fig. 1A shows that PDGF-treated cells subsequently ex-
posed to EGF and Sm-C or to 5% plasma exhibited high
rates of [3H]thymidine incorporation into trichloroacetic
acid precipitable material compared to PDGF-treated cells
left in 0.1% PPP without exogenous growth factors. Whereas
the monoclonal antibody, designated sm-1.2, had little influ-
ence on the baseline [3H]thymidine incorporation observed
in 0.1% PPP, it sharply inhibited [3H]thymidine incorpo-
ration induced by either 5% PPP or by Sm-C and EGF. The
residual stimulation of thymidine incorporation in the pres-
ence of plasma was not due to failure to inhibit IGF-I or
other somatomedin-like peptides in plasma since the residual
was identical in plasma-free medium containing only Sm-C
and EGF. When nuclear labeling was used as an index of
DNA synthesis (Fig. 1B), sm-1.2 produced a comparable in-
hibition of Sm-C-dependent labeling as that depicted in Fig.
1A. However, the antibody failed to influence the labeling
observed when 1 gg of insulin per ml was used as a somato-
medin surrogate. This is in keeping with the previously docu-
mented high specificity of the antibody for Sm-C.
These results (Fig. 1) were identical whether soluble anti-
body was incorporated directly into the incubation medium
or whether the experimental media were preincubated with
Sepharose-bound sm-1,2 to remove the growth factor prior
to exposure of the cells. Thus, the affinity of the antibody for
Sm-C appears to be sufficiently high that the growth factor
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FIG. 2. The effects of excess Sm-C on the inhibitory effect of
monoclonal antibody. Thymidine incorporation was determined as
described in the text. After exposure to PDGF for 5 hr, increasing
amounts of Sm-C were added to cultures containing EGF (10 ng/ml)
and sm-1.2 (1:4000).
The inhibitory effect of the Sm-C antibody on DNA syn-
thesis could be overcome by the addition of excess Sm-C.
Fig. 2 shows that Sm-C at 40-50 ng/ml fully restored the
mitogenic activity of culture medium containing EGF at 10
ng/ml and sm-1.2 at 1 ,ug/ml. To exclude the possibility that
the inhibitory effect of the monoclonal antibody might be
due to some other factor in the ascites fluid and not to the
antibody, we tested the effect of a similarly processed IgG
monoclone to horse apoferritin and observed no inhibition of
the stimulatory effect of Sm-C and EGF or of PPP (data not
shown).
The antibody was as effective in inhibiting the activity of
5% human plasma as it was against the combination of Sm-C
and EGF. Complete inhibition of the mitogenic effect of hu-
man plasma was evident up to a plasma concentration of
10% (Fig. 3A). The antibody also decreased the potency of
calf serum (Fig. 3B), but this effect was less complete. We
attribute these differences between human plasma and calf




























FIG. 1. The effects of monoclonal antibody on DNA synthesis induced in PDGF-primed BALB/c 3T3 cells by plasma and by the combina-
tion of EGF with Sm-C or insulin. (A) Thymidine incorporation. 0.1% PPP (0); Sm-C at 20 ng/ml and EGF at 10 ng/ml (e); and 5% PPP (A). All
results are expressed as the mean of triplicate wells SEM. (B) Autoradiography. 0.1% PPP (A); Sm-C at 20 ng/ml and EGF at 10 ng/ml (e);
insulin at 1 ug/ml and EGF at 10 ng/ml (0). Two predetermined fields were counted from each of two to four identical wells; results are

























FIG. 3. The effects of monoclonal antibody (1:4000) on the DNA synthesis induced by human PPP (A) and calf serum (B). Thymidine
incorporation was determined in the presence of plasma or serum alone (o) or in the presence of sm-1.2 diluted 1:4000 (o).
quirement of these cells for plasma (or Sm-C) is progressive-
ly decreased with increasing concentrations of PDGF (7).
These data lend strong support to the hypothesis that Sm-C
is a necessary component of plasma for the promotion of
growth in cultured cells.
A consistent finding in our studies was that sm-1.2 pro-
duced a small inhibition of the DNA synthesis induced by
EGF alone (Table 1). Since Leof et al. (10) found that EGF
could not support the progression of BALB/c 3T3 cells
through the early phases of G1 unless low concentrations of
Sm-C were simultaneously present, and since Sm-C is pro-
duced by many cell types in vitro (18), we postulated that the
small inhibition of DNA synthesis caused by the antibody
when only EGF was added to the medium was due to an
inhibitory effect of the antibody on small amounts of endoge-
nous Sm-C produced by the cells themselves. This was con-
firmed by finding that low but significant concentrations of
immunoreactive Sm-C accumulate in the medium of density-
inhibited BALB/c 3T3 cells cultured in the presence of
PDGF and EGF (data not shown). This interpretation is fur-
ther supported by the failure of the antibody to block the
mitogenic effect of EGF in the presence of insulin when add-
ed in sufficiently high concentrations to serve as a Sm-C sur-
rogate (Fig. 1B and Table 1).
To determine whether at some point in G1 commitment to
DNA synthesis no longer requires the presence of Sm-C, we
added the monoclonal antibody at progressively later time
intervals to the medium of PDGF-primed cells containing a
combination ofEGF and Sm-C and measured the rate of thy-
midine incorporation over 28 hr as described in Fig. 1A. As
shown in Fig. 4, addition of the antibody at any time prior to
hr 9 after adding Sm-C and EGF completely prevented entry
into DNA synthesis; thereafter, an increasing percentage of
the cells entered the S phase. Since the minimum transit time
through G1 after the addition ofEGF and Sm-C is 10 hr in the
absence of plasma (9), it can be concluded that irrevocable
Table 1. Inhibition of mitogenic effects by sm-1.2 in the absence
of added Sm-C
Antibody sm-1.2
Conditions (1:4000) cpm ± SEM
0.1%PPP - 33,609 ± 868
+ 22,270 ± 1087
Insulin (1 jug/ml) - 61,119 ± 2728
+ 61,291 ± 2295
EGF (10 ng/ml) - 82,476 ± 1724
+ 57,195 ± 2097
EGF (10 ng/ml) and - 126,364 ± 4494
insulin (1 Ag/ml) + 136,661 ± 2000
-, Without sm-1.2; +, with sm-1.2.
commitment to DNA synthesis requires Sm-C and occurs
approximately at the G1/S boundary. These findings agree
well with the "W" point of irrevocable commitment de-
scribed by Pledger et al. (19).
The present studies were confined to the effect of the anti-
body to Sm-C on DNA synthesis, although in other studies
(with Samuel D. Balk and David R. Clemmons) we have
shown that this antibody also inhibits Sm-C-dependent cell
proliferation in chicken heart mesenchymal cells and in por-
cine aortic smooth muscle cells, respectively. The studies
reported here demonstrate the potential utility of a monoclo-
nal antibody to Sm-C in defining the role of this peptide in
cellular growth and in probing the mechanisms of its action
at the cellular level. Our observation that confluent BALB/c
3T3 cells synthesize small amounts of immunoreactive Sm-C
extends the observations of others (20-22) that many cell
types are capable of somatomedin synthesis in vitro. Immu-
noneutralization appears to be a very potent tool for eluci-
dating the role of somatomedin produced endogenously by
cultured cells and organs. This "subtractive" approach will
also help to define the contribution of Sm-C to the biologic
effects of complex mixtures such as plasma and serum, al-
though at the concentrations used in these studies the anti-
body might not unequivocally discriminate between Sm-C
and IGF-II. Furthermore, this demonstration that the mono-







0 5 10 15 20 25 30
ANTIBODY ADDITION:
HOURS AFTER TRANSFER INTO Sm-C+ EGF
FIG. 4. The time course of Sm-C dependent commitment to
DNA synthesis. PDGF-primed cells were exposed to medium con-
taining Sm-C at 20 ng/ml, EGF at 10 ng/ml, and [3H]thymidine as
described. At the times indicated after the addition of growth fac-
tors, the medium of triplicate wells was replaced with identical me-
dium containing sm-1.2 diluted 1:4000. After 28 hr, the incorporation
of [3H]thymidine was arrested by the addition of ascorbic acid and
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way for its use to determine the biological role of the somato-
medins in the growth of living animals.
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